Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org
ESMO 2026
2026 年 10 月 23–27 日 · Madrid · 共 2910 条
#SCLC
6 人 · 6 条 · 8 篇摘要
本事件热度走势
当前热度 1·可比范围峰值 1（10月25日 01:00）·近 24 小时可比范围变化 –·当前参与者 1
参与者计数1
热度走势
深度解读
小细胞肺癌（SCLC）约占全部肺癌的15%，以极高的增殖率、强烈的早期转移倾向和不良预后为特征，多数患者确诊时已是转移性疾病[6]；美国SEER数据库显示，其在所有肺癌病理类型中的占比已从1986年的17.26%降至2002年的12.95%[5]。基因组层面，肿瘤几乎普遍存在TP53与RB1的功能失活[3][6]。治疗上，免疫治疗已在一线广泛期SCLC确立地位：CASPIAN III期试验在23个国家209个中心按1:1:1随机，比较durvalumab（±tremelimumab）联合铂类-依托泊苷与单纯化疗[4]，综述亦提到免疫治疗的近期引入改变了该瘤种的治疗格局[6]。这是解读本届ESMO任何SCLC免疫相关数据时必须参照的类别基线。
具体到本次会议，BMS官方账号预告将于明日以rapid oral形式报告一项分析：来自两项II期研究（分别为SCLC与三阴性乳腺癌TNBC）的脑转移亚组汇总结果，帖子同时带#BioNTech_Group标签；具体药物名称、主要终点与任何疗效或安全性数字均未披露，需待现场公布。同一批现场帖还包括Stephen V Liu的访谈，盘点本届ESMO最受期待的肺癌研究，以及Charles Rudin关于"问对问题才能找到对答案"的展望式发言——这两条属于会议前瞻与花絮，真正的新数据点只有上述脑转移亚组分析。
从推进角度看，这项读数的增量在于把观察窗口收窄到脑转移这一特定人群。背景综述已明确SCLC具有强烈的早期转移倾向、确诊时多数患者已处于转移状态[6]，而作为类别基石的CASPIAN，就所引摘要内容而言并未涉及脑转移亚组的疗效刻画[4]；将SCLC与TNBC两项II期研究的脑转移亚组放在同一场报告中集中读出，为中枢神经系统受累患者的疗效信号提供了一次集中检验的机会，也体现了在免疫治疗已确立的一线地位[4][6]之上向特殊人群深挖的思路。
局限同样清楚：其一，数据来自两项II期研究的亚组分析，证据等级与样本量均低于确证性III期试验[4]；其二，现场帖未给出任何数字，正式结论以会议报告原文为准；其三，访谈与引语属前瞻性内容，不构成疗效数据，读者不应据此作任何疗效或投资判断。
参考来源
- 1.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors · Sci Transl Med 2011
- 2.Interpreting the significance of changes in health-related quality-of-life scores · J Clin Oncol 1998
- 3.Comprehensive genomic profiles of small cell lung cancer · Nature 2015
- 4.Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial · Lancet 2019
- 5.Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database · J Clin Oncol 2006
- 6.Small-cell lung cancer · Nat Rev Dis Primers 2021
证据
2631RO
First-line BAT8008 (TROP2-ADC) plus BAT1308 (anti-PD-1) for advanced NSCLC: Results from a multicenter phase 2 study
https://esmocongress.esmo.org2636RO
Characterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study
https://esmocongress.esmo.org2658RO
Overall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human study
https://esmocongress.esmo.org2660P
Phase 2 trial of the PD-1/VEGF bispecific antibody, PF-08634404 (SSGJ-707), plus chemotherapy (chemo) in advanced NSCLC: Updated results
https://esmocongress.esmo.org2683P
First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.org2700RO
Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort
https://esmocongress.esmo.org2719RO
FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)
https://esmocongress.esmo.org现场
Enes Erul MD@ErulEnes Lung Cancers Today@Lung_Cancers sevinç ballı@sevincballi 当我们提出正确的问题时，我们将找到正确的答案。 @charlesrudin #sclc #esmo26 @OncoAlert @myESMO
FJ ⭐️⭐️+⭐️@pistoto2017 #SCLC #lungcancer #ESMO26 @myESMO
引用@@dr_yakupergun @SuyogCancer @myESMO @OncBrothers @KolPulseAI In my view, your opinions regarding DeLLphi-305 and IMforte are very sensible and very intelligent.Congrats! Unfortunately, #Tarlatamab is not for every patient, it cannot be administered in every setting, and it is not the most economical option. This must be taken into account.
暂无中文译文，显示英文原文。
AACR 2026 现场信号@ AACR 2026 现场信号@ AACR 2026 现场信号@ Karen Woodward@karenbythelee24 This is fabulous news for ES-SCLC #SCLC #ESMO26
引用@Richly deserved standing ovation for @sands_jacob setting a new standard for the treatment of ES-SCLC #ESMO26
暂无中文译文，显示英文原文。
Science At BMS@ScienceAtBMS LUNGevity Foundation@LUNGevity LUNGevity Foundation@LUNGevity